Literature DB >> 9196521

Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange.

P Jolliet1, P Bulpa, J B Thorens, M Ritz, J C Chevrolet.   

Abstract

BACKGROUND: In patients with primary pulmonary hypertension who respond to vasodilators acutely, survival can be improved by the long term use of calcium channel blockers. However, testing for such a response with calcium channel blockers or prostacyclin (PGI2) may cause hypotension and adversely affect gas exchange. Nitric oxide (NO), which does not have these effects, could be a better test agent.
METHODS: NO (10, 20, and 40 ppm for 15 minutes), PGI2 (1-->10 ng/kg/min), and oral nifedipine (10 mg, then 20 mg/h) were administered sequentially to 10 patients after determination of the 24 hour spontaneous variability of their pulmonary and systemic mean arterial pressures. Patients were considered responders if the mean pulmonary artery pressure or pulmonary vascular resistance decreased by 20% or more.
RESULTS: Six patients (60%) responded to all three agents, and three to none of the agents. One patient responded to PGI2 only. In those who responded to vasodilators, NO had no major effect on gas exchange or systemic haemodynamics, while PGI2 and nifedipine both induced systemic hypotension (mean (SD) systemic arterial pressure 72 (14) versus 89 (19) mm Hg with PGI2 and 72 (15) versus 86 (17) mm Hg with nifedipine, p < 0.05) and hypoxaemia (PaO2 8.7 (1.4) versus 10.8 (1.0) kPa with PGI2 and 8.6 (1.4) versus 10.2 (1.5) kPa with nifedipine, p < 0.05) and increased venous admixture (28 (9) versus 14 (4)% with PGI2 and 22 (9) versus 13 (5)% with nifedipine, p < 0.05).
CONCLUSIONS: NO inhalation can accurately predict a vasodilator response to nifedipine in patients with severe pulmonary hypertension without adverse effects on systemic haemodynamics and gas exchange. This absence of side effects may make it a more appropriate agent for testing the vasodilator response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9196521      PMCID: PMC1758528          DOI: 10.1136/thx.52.4.369

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine.

Authors:  J Partanen; M S Nieminen; K Luomanmäki
Journal:  N Engl J Med       Date:  1993-09-09       Impact factor: 91.245

2.  Influence of cardiac output on intrapulmonary shunt.

Authors:  J P Lynch; J G Mhyre; D R Dantzker
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1979-02

3.  Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension.

Authors:  H I Palevsky; W Long; J Crow; A P Fishman
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

4.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

5.  Prostaglandin I2 supports blood flow to hypoxic alveoli in anesthetized dogs.

Authors:  R S Sprague; A H Stephenson; A J Lonigro
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-05

6.  Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

Authors:  O Sitbon; F Brenot; A Denjean; A Bergeron; F Parent; R Azarian; P Herve; B Raffestin; G Simonneau
Journal:  Am J Respir Crit Care Med       Date:  1995-02       Impact factor: 21.405

7.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

Authors:  E K Weir; L J Rubin; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; C G Elliott; A P Fishman; R M Goldring; B M Groves
Journal:  Am Rev Respir Dis       Date:  1989-12

8.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

Authors:  S Rich; B H Brundage
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

9.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

  9 in total
  7 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 2.  Pulmonary hypertension: its assessment and treatment.

Authors:  S Brij; A J Peacock
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

3.  Cor Pulmonale.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

4.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 5.  Assessment and treatment of right ventricular failure.

Authors:  Marc A Simon
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

6.  Inhaled nitric oxide alters the distribution of blood flow in the healthy human lung, suggesting active hypoxic pulmonary vasoconstriction in normoxia.

Authors:  Amran K Asadi; Rui Carlos Sá; Nick H Kim; Rebecca J Theilmann; Susan R Hopkins; Richard B Buxton; G Kim Prisk
Journal:  J Appl Physiol (1985)       Date:  2014-11-26

7.  Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.

Authors:  W Budts; N Van Pelt; H Gillyns; M Gewillig; F Van De Werf; S Janssens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.